Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-032587
Filing Date
2025-03-04
Accepted
2025-03-04 18:01:09
Documents
1
Period of Report
2025-03-01

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 7159
  Complete submission text file 0000950170-25-032587.txt   8725
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Issuer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O INTRA-CELLULAR THERAPIES, INC. 135 ROUTE 202/206 BEDMINSTER NJ 07921
Business Address
Mates Sharon (Reporting) CIK: 0001585699 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36274 | Film No.: 25707116